Business Context and Reporting Period
Immuron Limited, a foreign private issuer, filed this Form 6-K for the month of June 2019, dated June 12, 2019. The filing serves to disclose a public announcement made to the Australian Securities Exchange regarding clinical study results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific corporate event rather than a financial statement.
Material Changes
The material change disclosed is the publication of results from a study on Travelan for Shigellosis conducted by the US Department of Defense (DoD). No financial performance changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
The filing includes an exhibit titled "US DoD Reports Results from Travelan Shigellosis Study." The document does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard legal disclaimers regarding the filing status under the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific clinical outcomes of the US DoD Travelan Shigellosis Study by reviewing Exhibit 99.1.
- Confirm the impact of these study results on the company's regulatory pathway for Travelan.
- Review the company's most recent Form 20-F for actual financial performance data, as this Form 6-K contains no financial metrics.